JPWO2023089587A5 - - Google Patents
Info
- Publication number
- JPWO2023089587A5 JPWO2023089587A5 JP2024529873A JP2024529873A JPWO2023089587A5 JP WO2023089587 A5 JPWO2023089587 A5 JP WO2023089587A5 JP 2024529873 A JP2024529873 A JP 2024529873A JP 2024529873 A JP2024529873 A JP 2024529873A JP WO2023089587 A5 JPWO2023089587 A5 JP WO2023089587A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cys
- amino acid
- scfv
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163281954P | 2021-11-22 | 2021-11-22 | |
| US63/281,954 | 2021-11-22 | ||
| US202263322158P | 2022-03-21 | 2022-03-21 | |
| US63/322,158 | 2022-03-21 | ||
| US202263393750P | 2022-07-29 | 2022-07-29 | |
| US63/393,750 | 2022-07-29 | ||
| PCT/IB2022/061241 WO2023089587A1 (en) | 2021-11-22 | 2022-11-21 | Compositions comprising enhanced multispecific binding agents for an immune response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024542235A JP2024542235A (ja) | 2024-11-13 |
| JP2024542235A5 JP2024542235A5 (https=) | 2025-12-01 |
| JPWO2023089587A5 true JPWO2023089587A5 (https=) | 2025-12-01 |
Family
ID=84370675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529873A Pending JP2024542235A (ja) | 2021-11-22 | 2022-11-21 | 免疫応答のための増強された多重特異性結合剤を含む組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250320304A1 (https=) |
| EP (1) | EP4436669A1 (https=) |
| JP (1) | JP2024542235A (https=) |
| KR (1) | KR20240111783A (https=) |
| AU (1) | AU2022392829A1 (https=) |
| CA (1) | CA3239224A1 (https=) |
| IL (1) | IL312968A (https=) |
| MX (1) | MX2024006205A (https=) |
| WO (1) | WO2023089587A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025034715A1 (en) * | 2023-08-07 | 2025-02-13 | Janssen Biotech, Inc. | Gucy2c antibodies and uses thereof |
| US20250361317A1 (en) | 2024-05-24 | 2025-11-27 | Janssen Biotech, Inc. | Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| US10344050B2 (en) | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| KR102216003B1 (ko) | 2013-03-15 | 2021-02-16 | 얀센 바이오테크 인코포레이티드 | 재조합 단백질에서 c-말단 라이신, 갈락토스 및 시알산 함량을 제어하기 위한 제조 방법 |
| CN110894240B (zh) * | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| ES2897217T3 (es) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
| TW202120537A (zh) * | 2019-08-15 | 2021-06-01 | 美商健生生物科技公司 | 用於經改善的單鏈可變片段之材料及方法 |
-
2022
- 2022-11-21 CA CA3239224A patent/CA3239224A1/en active Pending
- 2022-11-21 EP EP22817370.4A patent/EP4436669A1/en active Pending
- 2022-11-21 KR KR1020247020460A patent/KR20240111783A/ko active Pending
- 2022-11-21 JP JP2024529873A patent/JP2024542235A/ja active Pending
- 2022-11-21 IL IL312968A patent/IL312968A/en unknown
- 2022-11-21 MX MX2024006205A patent/MX2024006205A/es unknown
- 2022-11-21 WO PCT/IB2022/061241 patent/WO2023089587A1/en not_active Ceased
- 2022-11-21 US US18/711,312 patent/US20250320304A1/en active Pending
- 2022-11-21 AU AU2022392829A patent/AU2022392829A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11879005B2 (en) | Hetero-dimeric multi-specific antibody format | |
| US20210189011A1 (en) | Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation | |
| CN107207592B (zh) | 结构域交换的抗体 | |
| JP2019533441A5 (https=) | ||
| JP7600327B2 (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| US20200181263A1 (en) | Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa | |
| CN119032104A (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| JP2025160226A5 (https=) | ||
| KR20230148169A (ko) | 항-pd-l1 모노클로날 항체 및 인터루킨-15 (il-15), 인터루킨-15 수용체 15 알파 또는 인터루킨-2와의 융합 단백질 | |
| JP2023139025A (ja) | 二重特異性抗原結合コンストラクト | |
| WO2019199916A1 (en) | Fab-based trispecific antibodies | |
| JP7826320B2 (ja) | 二重または多重特異性抗体｛Ｂｉ ｏｒ Ｍｕｌｔｉ－Ｓｐｅｃｉｆｉｃ Ａｎｔｉｂｏｄｙ｝ | |
| JPWO2023089587A5 (https=) | ||
| WO2024061224A1 (zh) | 抗her2抗体及其用途 | |
| RU2024116415A (ru) | Композиции, содержащие улучшенные мультиспецифические связывающие агенты для иммунного ответа | |
| JPWO2021148006A5 (https=) | ||
| WO2025092987A1 (zh) | 基于Fc区的异二聚体分子及其用途 | |
| JP2022028645A5 (https=) | ||
| HK40050601A (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
| RU2022103028A (ru) | Антитела против рецептора программируемой смерти pd-1 человека | |
| HK1247929A1 (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
| RU2022133024A (ru) | Анти-cd3 антитело и молекула, содержащая это антитело | |
| RU2019122411A (ru) | Анти сd3 антитело и молекула, содержащая это антитело | |
| HK1247929B (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
| HK1194744B (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation |